GlaxoSmithKline (GSK) Pharma is focusing on building a preventive healthcare ecosystem led by adult vaccines. With nearly thirty crore prescriptions annually, GSK Pharma is set to venture into the oncology sector by launching two high-value therapies. This marks a shift beyond its established general medicine offerings.
The company is broadening its preventive healthcare portfolio by introducing more adult vaccines, transitioning from its traditional focus on infant immunizations to a comprehensive approach for all age groups.
Since GSK’s global transition to a biopharma company, the Indian portfolio has undergone a transformation, driven by innovation. Newer therapies are now contributing to the company’s growth.
The transformation comes as part of a global trend where pharmaceutical companies are moving away from generic portfolios to focus on high-value therapeutics. GSK is committed to fast-tracking the launch of relevant innovative assets in India. The company has already obtained marketing authorization for oncology drugs, including zejula and jemperli, for ovarian and endometrial cancer treatments, respectively.
To expand its reach, GSK is adopting innovative solutions such as an omnichannel strategy, including a digital platform for vaccine orders. Healthcare professionals can now manage inventory and place orders through an app similar to Amazon’s.
As reported by timesofindia.indiatimes.com, GSK’s pediatric vaccine portfolio in India includes products like infanrix hexa, havrix, varilrix, menveo, boostrix, and fluarix. Currently, vaccines account for 20% of GSK’s total turnover, but the company aims for double-digit growth by optimizing its operations.
